SEC Form 4 · accession 0001209191-16-127040

AGIOS PHARMACEUTICALS, INC. · AGIO

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — Chief Scientific Officer

Period of report

Jun 8, 2016

Accepted (ET)

Jun 10, 2016 · 4:03 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001439222

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common stock	Jun 8, 2016	M	22,306	$0.4675	A	81,376	D
Common stock	Jun 8, 2016	M	5,194	$31.64	A	86,570	D
Common stock	Jun 8, 2016	S	27,500	$65.00	D	59,070	D
Common stock	Jun 10, 2016	M	15,200	$0.4675	A	74,270	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock option (right to buy)^F3	$0.4675	Jun 8, 2016	M	22,306	D	—	Dec 6, 2020	Common stock	22,306	306,385	D
Stock option (right to buy)^F4	$31.64	Jun 8, 2016	M	5,194	D	—	Mar 4, 2024	Common stock	5,194	301,191	D
Stock option (right to buy)^F3	$0.4675	Jun 10, 2016	M	15,200	D	—	Dec 6, 2020	Common stock	15,200	285,991	D

F1This exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F2This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
F3This option was granted on December 7, 2010. The shares underlying this option vest as to 25% of the shares on September 20, 2011, with the remaining 75% vesting in 36 equal monthly installments thereafter.
F4This option was granted on March 5, 2014. The shares underlying this option vest as to 25% of the shares on March 5, 2015, with the remaining 75% vesting in 36 equal monthly installments thereafter.